Research programme: histamine H3 receptor antagonists - Merck & Co
Latest Information Update: 16 Jul 2016
At a glance
- Originator Schering-Plough
- Developer Merck & Co
- Class Piperidines; Small molecules; Thiadiazoles; Urea compounds
- Mechanism of Action Histamine H3 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Allergic rhinitis; Obesity; Type 2 diabetes mellitus
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Type-2-diabetes-mellitus in USA (PO)
- 16 Jul 2016 No recent reports of development identified for research development in Obesity in USA (PO)
- 23 Aug 2012 Preclinical trials in Type-2 diabetes mellitus in USA (PO)